Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Israeli Medtech Leaders Say War Is Impacting Companies, Driving Industry Humanitarian Effort

Executive Summary

Two executives of Israeli-based medtech companies say the Hamas-Israeli war is having an impact on their companies, with employees being called up as reservists and others needing accommodations. It also has galvanized companies to join forces to support health and humanitarian needs during the crisis.

You may also be interested in...



TytoCare Plans To Integrate More AI Into Diagnostics To Drive Longitudinal ‘Family’ Care At Home

Medtech Insight recently sat down with TytoCare’s chief commercial officer Tamir Gotfried to discuss plans for driving virtual care in the home, and engage physicians and consumers, at a time when pandemic-era state-level telehealth flexibilities continue to evolve.

Mosie Baby First To Win FDA Clearance For At-Home Artificial Insemination Kit

Austin-based start-up Mosie received FDA clearance for a home insemination kit to help people get pregnant. The kit retails for $129.99.

Newer Therapy Areas Will Drive Women’s Health Funding In 2024

Women’s health startups focusing on areas of high unmet need such as menopause, infertility, preventive care and post-partum care will continue to attract investors in 2024. Meanwhile, machine learning and AI, as well as next-generation treatments such as psychedelic therapy, stand to drive advancements in the space.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel